European Investor
08 Feb 2026, 18:42
Galapagos NV announced that its Board of Directors has formally decided to initiate the wind-down of its cell therapy activities, following the completion of works council consultations in Belgium and the Netherlands.
The decision follows a strategic review and sale process announced in October 2025, during which the company explored divestment options for the cell therapy business. The wind-down will affect approximately 365 employees across Europe, the United States and China, and will lead to the closure of sites in Leiden, Basel, Princeton, Pittsburgh and Shanghai.
Chief Executive Officer Henry Gosebruch said the company is now focused on executing the wind-down while continuing Galapagos’ transformation through business development. After completion, Galapagos will reposition its remaining organization for long-term growth, maintaining its headquarters in Mechelen, Belgium, and U.S. hubs in Chicago and San Francisco.
Non-cell therapy activities will continue, including the TYK2 program GLPG3667, for which Galapagos will evaluate strategic alternatives such as renewed partnering to advance development in dermatomyositis and potentially other severe autoimmune diseases. As of 31 December 2025, the company held approximately €3.0 billion in cash, cash equivalents and financial investments, and plans to provide further details on wind-down costs, timing and updated financial guidance with its full-year 2025 results in late February 2026.
The decision follows a strategic review and sale process announced in October 2025, during which the company explored divestment options for the cell therapy business. The wind-down will affect approximately 365 employees across Europe, the United States and China, and will lead to the closure of sites in Leiden, Basel, Princeton, Pittsburgh and Shanghai.
Chief Executive Officer Henry Gosebruch said the company is now focused on executing the wind-down while continuing Galapagos’ transformation through business development. After completion, Galapagos will reposition its remaining organization for long-term growth, maintaining its headquarters in Mechelen, Belgium, and U.S. hubs in Chicago and San Francisco.
Non-cell therapy activities will continue, including the TYK2 program GLPG3667, for which Galapagos will evaluate strategic alternatives such as renewed partnering to advance development in dermatomyositis and potentially other severe autoimmune diseases. As of 31 December 2025, the company held approximately €3.0 billion in cash, cash equivalents and financial investments, and plans to provide further details on wind-down costs, timing and updated financial guidance with its full-year 2025 results in late February 2026.